<DOC>
	<DOCNO>NCT01015456</DOCNO>
	<brief_summary>To investigate efficacy safety enteric-coated mycophenolate sodium ( Myfortic ) compare intravenous cyclophosphamide treatment active nephritis . The primary outcome complete partial renal remission , assess renal function , urinary sediment proteinuria patient International Society Nephrology/ Renal Pathology Society ( ISN/RPS ) class III IV lupus nephritis .</brief_summary>
	<brief_title>The Efficacy Enteric-coated Mycophenolate Sodium ( EC-MPS ) ( Myfortic ) The Treatment Relapse Resistant Proliferative Lupus Nephritis</brief_title>
	<detailed_description>In study , two sub-studies order define secondary endpoint . 1 . Pharmacokinetics study Mycophenolic acid 2 . Identify biomarkers therapy-resistant prediction . 3 . Identify biomarkers predict loss kidney function .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>age 16 year time screen ability willingness provide write informed consent ( obtain consent parent guardian applicable ) comply schedule protocol requirement Diagnosis SLE accord ACR criterion . At least 4 criterion must present diagnosis SLE . The 4 criterion present time screen Active lupus nephritis define follow : Biopsy proven ( within 16 week prior screen ) ISN Class III IV ( A A/C ) include III ( C ) IV ( C ) VI ( &gt; 90 % chronic irreversible scar ) Relapse resistant ( 3 consecutive dos ) IVCY Resistant lupus Relapse lupus nephritis define follow : Increase serum creatinine &gt; /= 0.3 mg/dl Increase proteinuria &gt; 1.5 g/day ( must improve ≥ 50 % precede 3 month ) Lifetime cumulative dose IVCY &gt; 6 gram Female patient childbearing potential must negative serum pregnancy Relates SLE Diagnosis rapid progressive glomerulonephritis ( RPGN ) : double serum creatinine and/or crescentic glomerulus ≥ 30 % Severe renal impairment define calculated creatinine clearance MDRDGFR &lt; 30 ml/min ( except creatinine clearance MDRDGFR &gt; 50 ml/min 12 week prior screen ) History serious disease complication organ system appropriate treatment immunosuppressive drug group . Severe extrarenal organ involvement Related Treatment Previous Mycophenolate group 6 month prior screen Treatment investigational drug 3 month prior screen Related General Health Pregnancy breast feeding mother . Concomitant condition require treatment moderate high dose steroid 12 week prior screen . Evidence significant uncontrolled concomitant disease organ system related SLE . History cancer , include solid tumor , hematological malignancy carcinoma . Evidence current abuse drug alcohol . Related Laboratory Findings Neutrophile &lt; 1,500/mm3 , Hb &lt; 7g/L , Platelet &lt; 50,000/mm3 ( except active SLE ) Positive HBsAg antiHCV antiHIV .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>lupus nephritis</keyword>
	<keyword>mycophenolate sodium</keyword>
	<keyword>cyclophosphamide</keyword>
</DOC>